Smith Salley Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

Smith Salley Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,048	Closed	-$16.5K	–	232
2022 Q4	$16.5K	Hold	12,048	–	–	﹤0.01%	222
2022 Q3	$13K	Hold	12,048	–	–	﹤0.01%	213
2022 Q2	$13K	Hold	12,048	–	–	﹤0.01%	227
2022 Q1	$13K	Buy	+12,048	New	+$11K	﹤0.01%	239

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Smith Salley Wealth Management's PLX Position: Q1 2023 in Review

Smith Salley Wealth Management sold out of Protalix BioTherapeutics (PLX) in Q1 2023, closing a stake of 12,048 shares — an estimated $16.5K sold.

Smith Salley Wealth Management first reported a position in PLX in Q1 2022 and held it in 4 quarters. The position peaked at $16.5K in Q4 2022. 34 funds tracked by Wall St. Rank hold PLX as of Q1 2023.

Smith Salley Wealth Management reported no remaining Protalix BioTherapeutics position as of Q1 2023 after selling out during the quarter.
Smith Salley Wealth Management sold 12,048 Protalix BioTherapeutics shares in Q1 2023, an estimated $16.5K.
Smith Salley Wealth Management first reported a position in Protalix BioTherapeutics in Q1 2022 and held it in 4 quarters.
Smith Salley Wealth Management's Protalix BioTherapeutics position peaked at $16.5K in Q4 2022.
34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2023.

Based on Smith Salley Wealth Management's 13F filing for Q1 2023, filed 3 May 2023.